Get started
Author

David Marrupe

Observed names: D. Marrupe, D. Marrupe Gonzalez, D. Marrupe González, David Marrupe Gonzalez, David Marrupe González, David Marrupe-González
Observed institutions: Universidad Francisco de Vitoria, Hospital Universitario Nuestra Señora de Candelaria, Hospital General Nuestra Señora del Prado, Institut Català d'Oncologia, Hospital Universitario de Móstoles, Complejo Hospitalario de Ourense, Sociedad Española de Oncología Médica
ORCID: 0000-0002-7986-2783
Observed ORCID: 0000-0002-7986-2783
OpenAlex ID: A5014795258
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial
2019 · Peter Vink, Ignacio Delgado Mingorance, et al. · Cancer · 132
PDF
Clinical outcomes of FOLFIRINOX and gemcitabine–nab paclitaxel for metastatic pancreatic cancer in the real world setting
2020 · F. Franco, J. C. Camara, et al. · Clinical & Translational Oncology · 21
Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study
2023 · Sara Lopez-Tarruella, María Del Monte-Millán, et al. · Breast Cancer Research and Treatment · 19
PDF
Colestasis idiopática asociada a ductopenia progresiva en dos pacientes con linfoma de Hodgkin
2002 · C. Ripoll, R. Bañares, et al. · Gastroenterología y Hepatología · 19
Role of GALNT12 in the genetic predisposition to attenuated adenomatous polyposis syndrome
2017 · Víctor Lorca, Daniel Rueda, et al. · PLoS ONE · 11
PDF
Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients
2022 · Laura Pena-Couso, María Ercibengoa, et al. · Orphanet Journal of Rare Diseases · 8
PDF
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
2016 · Nuria Lainez, Jesús García-Donas, et al. · BMC Cancer · 8
PDF
Clinical outcomes of FOLFIRINOX and gemcitabine-nab-paclitaxel for metastatic pancreatic cancer in the real-world setting.
2020 · Fabio Franco, Jose Ignacio Martin Valades, et al. · Journal of Clinical Oncology · 6
Pazopanib in metastatic renal carcinoma (mRC): Experience of 31 centers in Spain in first, second, third, or subsequent lines in daily clinical practice.
2013 · Angel Rodriguez Sanchez, Rocio García Domínguez, et al. · Journal of Clinical Oncology · 5
Un caso de carcinoma de trompa de Falopio
2006 · F. Marcos Sánchez, E. Sánchez Díaz, et al. · Anales de Medicina Interna · 3
PDF
Tumour SNPs Associated with Immune-Related Hepatitis in Patients with Melanoma Receiving Immune Checkpoint Inhibitors
2025 · Jose María Rodríguez-Piñas, Alicia Romero-Lorca, et al. · Biomedicines · 2
PDF
Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding
2024 · Silvia García Adrián, Claudia Iglesias Pérez, et al. · Haematologica · 2
PDF
85P Correlation between nCOUNTER PAM-50 assay and three IHC-based surrogate intrinsic breast cancer subtype classifiers: A real-world study
2022 · M. Martín, M. Del Monte-Millán, et al. · Annals of Oncology · 2
PDF
Clinical outcomes of FOLFIRINOX and gemcitabine/nab-paclitaxel in the real world setting.
2018 · Fernando Franco Franco, Camara Juan C, et al. · Journal of Clinical Oncology · 2
Hiperlipidemia inducida por tamoxifeno
2005 · F. Marcos Sánchez, A. Viana Alonso, et al. · Anales de Medicina Interna · 2
PDF
Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants
2026 · JM Rodríguez-Piñas, A. Romero-Lorca, et al. · The Pharmacogenomics Journal · 1
PDF
Venous thrombosis in lung cancer compared with other tumors: results from the TESEO-SEOM registry
2025 · Claudia Iglesias-Perez, Paula Jimenez-Fonseca, et al. · Thrombosis Research · 1
Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients
2019 · M. de Toro Carmena, L. Ortega Morán, et al. · Annals of Oncology · 1
PDF
Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX+ bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left (L)-sided, unresectable colorectal cancer (CRC): The CR-SEQUENCE.
2019 · Ramon Salazar, Alfredo Carrato, et al. · Journal of Clinical Oncology · 1
Efficacy of therapies after progression to up-front docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC)
2018 · P. Gajate Borau, A. Martin Marino, et al. · Annals of Oncology · 1
How do patterns of progression influence treatment selection after chemohormonal therapy in patients with metastatic hormone sensitive prostate cancer?
2017 · Carlos Aguado De La Rosa, Iciar Garcia Carbonero, et al. · Journal of Clinical Oncology · 1
Clinical experience with carboplatin (CBDCA) and oral vinorelbine (NVBO) in first-line advanced non-small cell lung cancer (NSCLC) treatment.
2010 · S. Garcia Adrian, J. Firvida, et al. · Journal of Clinical Oncology · 1
Tumor-derived microRNAs as early predictive biomarkers for toxicity induced by immunotherapy in urothelial cancer
2026 · Maria Gaibar, Alicia Romero-Lorca, et al. · Journal of Cancer Research and Clinical Oncology
Tumor miRNA expression as a potential biomarker of immune-related toxicity in patients with melanoma or urothelial carcinoma treated with immune checkpoint inhibitors.
2026 · Beatriz Anton Pascual, Jose Maria Rodriguez-Piñas, et al. · Journal of Clinical Oncology
Tinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design
2025 · Mercedes Salgado, Juan de la Camara-Gómez, et al. · BMC Cancer
PDF
Works count: 31
Citation count: 249
H-index: 7
I10-index: 5
Year
Topic
Type